Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleTracy Tomlinson, 58, was given the experimental drug, ZI-MA4-1, at the Christie NHS Foundation Trust in Manchester (Family handout/PA)Tracy Tomlinson, 58, with advanced ovarian cancer, has become the first patient globally to receive the experimental drug ZI-MA4-1 as part of a clinical trial at the Christie NHS Foundation Trust in Manchester. The therapy combines natural killer (NK) cells with engineered T-cell receptors (TCRs) to specifically target the Mage-A4 protein found in various cancer types, including ovarian, lung, sarcomas and head and neck cancer. Unlike personalised treatments, ZI-MA4-1 is an "off-the-shelf" therapy manufactured from donor immune cells, aiming to make advanced cell therapies more accessible, quicker, and cheaper for a wider patient population. Mrs Tomlinson, diagnosed in 2020, has undergone multiple treatments, with her cancer repeatedly returning, and hopes this new therapy will benefit her and future patients. Experts from the Christie and Zelluna, the drug's manufacturer, highlight this as a landmark moment in cancer treatment, representing a novel approach in cell therapy with significant potential for solid tumours. In fullManchester ovarian cancer patient becomes world’s first person to receive ‘landmark’ treatmentMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Cancer patient becomes first in world to receive pioneering new therapy
Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleTracy Tomlinson, 58, was given the experimental drug, ZI-MA4-1, at the Christie NHS Foundation Trust in Manchester (Family handout/PA)Tracy Tomlinson, 58, with advanced ovarian cancer, has become the first patient globally to receive the experimental drug ZI-MA4-1 as part of a clinical trial at the Christie NHS Foundation Trust in Manchester. The therapy combines natural killer (NK) cells with engineered T-cell receptors (TCRs) to specifically target the Mage-A4 protein found in various cancer types, including ovarian, lung, sarcomas and head and neck cancer. Unlike personalised treatments, ZI-MA4-1 is an "off-the-shelf" therapy manufactured from donor immune cells, aiming to make advanced cell therapies more accessible, quicker, and cheaper for a wider patient population. Mrs Tomlinson, diagnosed in 2020, has undergone multiple treatments, with her cancer repeatedly returning, and hopes this new therapy will benefit her and future patients. Experts from the Christie and Zelluna, the drug's manufacturer, highlight this as a landmark moment in cancer treatment, representing a novel approach in cell therapy with significant potential for solid tumours. In fullManchester ovarian cancer patient becomes world’s first person to receive ‘landmark’ treatmentMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
